Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Misses Estimates By $0.02 EPS

Pyxis Oncology (NASDAQ:PYXS) issued its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), Zacks reports.

Pyxis Oncology Trading Up 3.2%

Shares of PYXS traded up $0.07 during trading hours on Friday, reaching $2.28. 986,489 shares of the stock traded hands, compared to its average volume of 643,306. The stock has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $2.30. Pyxis Oncology has a 52 week low of $0.97 and a 52 week high of $5.55. The company has a market cap of $143.30 million, a price-to-earnings ratio of -1.77 and a beta of 1.43.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PYXS. Maia Wealth LLC bought a new position in shares of Pyxis Oncology during the fourth quarter valued at about $25,000. Engineers Gate Manager LP bought a new position in shares of Pyxis Oncology during the fourth quarter valued at about $26,000. Fox Run Management L.L.C. bought a new position in shares of Pyxis Oncology during the fourth quarter valued at about $26,000. XTX Topco Ltd bought a new position in shares of Pyxis Oncology during the second quarter valued at about $40,000. Finally, LPL Financial LLC raised its position in Pyxis Oncology by 150.7% in the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after acquiring an additional 21,100 shares during the period. 39.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wedbush assumed coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 13th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.83.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.